Biostar Pharma (02563.HK) is a national high-tech enterprise founded by a team of scientists from the United States. Leveraging its advanced and sustainable synthetic biology new drug R&D platform, the company focuses on developing innovative anticancer drugs with independent intellectual property rights. After more than 20 years of development, the company has evolved into an integrated biopharmaceutical company encompassing new drug R&D, manufacturing, and commercialization. Its independently developed National Class 1 new drug, Utidelone Injection (brand name: Utidel®), is a next-generation microtubule inhibitor produced through microbial fermentation process and was approved for marketing by the National Medical Products Administration in March 2021. In 2020, Efung Capital invested in Biostar Pharma. On October 31, 2024, Biostar Pharma was listed on the Main Board of the Hong Kong Stock Exchange.